DS 2969

Drug Profile

DS 2969

Alternative Names: DS2969

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Antidiarrhoeals
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Clostridium infections

Most Recent Events

  • 25 Oct 2017 Adverse events, pharmacokinetics and antimicrobial data from a phase I trial in Healthy volunteers presented at the Infectious Disease Week-2017 (IDW-2017)
  • 18 May 2017 DS 2969 is available for licensing in USA as of 18 May 2017. http://www.daiichisankyo.com/ (Daiichi Sankyo pipeline, May 2017)
  • 01 Jan 2016 Phase-I clinical trials in Clostridium infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top